Immunotherapy in the Frontline Demonstrates Promise in mRCC With Poor Performance Status

Article

Patients with metastatic renal cell carcinoma and a performance status of 2 or more experienced promising clinical activity from treatment with nivolumab/ipilimumab and pembrolizumab/axitinib.

Treatment with nivolumab (Opdivo) plus ipilimumab (Yervoy) and pembrolizumab (Keytruda) plus axitinib (Inlyta) yielded comparable and promising safety and efficacy in patients with metastatic renal cell carcinoma (mRCC) and a performance status of 2 or greater, according to data that were presented at 2022 Genitourinary Cancers Symposium.

At a median follow-up of 11.1 months, the overall objective response rate (ORR) was 27%; the ORR was numerically higher with pembrolizumab/axitinib (42%) vs nivolumab/ipilimumab (20%) but did not reach statistical significance (P = .157).

The overall median progression-free survival (PFS) was 4.4 months, and the median overall survival (OS) was 15.9 months.

“We report the first cohort of performance status ≥2 mRCC patients treated with checkpoint inhibitor combinations in the first-line setting. No significant difference in ORR, PFS, or OS was seen between nivolumab/ipilimumab and pembrolizumab/axitinib,” the study authors wrote in the poster.

Dual checkpoint inhibition is a standard frontline treatment regimen for patients with mRCC. However, patients with a performance status of 2 or greater were not eligible for enrollment in the pivotal trials, leaving the efficacy and safety of these regimens unknown in this population.

As such, a multicenter study was performed, evaluating 56 patients with mRCC with a performance status of 2 or greater treated with the frontline combination of nivolumab and ipilimumab (n = 36) or pembrolizumab and axitinib (n = 20) across 13 institutions between 2017 and 2021.

ORR, disease control rate (DCR), PFS, OS, and grade 3 or greater treatment-related adverse effects (TRAEs) were evaluated. The association between Lung Immune Prognostic Index (LIPI) score and ORR, PFS, and OS was also evaluated.

The median age at diagnosis was 64 years (range, 31-83). Most patients were male (n = 38; 67.9%); 16 (28.6%) had undergone nephrectomy, and 40 (71.4%) had synchronous metastatic disease at diagnosis.

Most patients had a good LIPI score (n = 18; 32.1%), followed by intermediate (n = 13; 23.2%) and poor (n = 5; 8.9%); 36 patients’ data was not applicable. Additionally, most patients had a Fuhrman grade of III (n = 21; 37.5%), followed by II (n = 15; 26.8%), IV (n = 5; 8.9%), and I (n = 2; 3.6%).

A total of 19 (33.9%) and 37 (66.1%) patients had intermediate and poor risk, respectively, according to the International Metastatic RCC Database Consortium (IMDC). A total of 50 patients (89.3%) had clear cell RCC, and 4 patients (7.1%) had sarcomatoid features.

At data cutoff, 45% of patients had died.

Additional results showed that no significant difference in median OS (P = .362), median PFS (P = .536), or the rate of grade 3 or greater TRAEs was found between the pembrolizumab/axitinib and nivolumab/ipilimumab regimens (24% vs 22%, respectively; P =1.0). Moreover, no significant difference in median OS or median PFS was seen, according to IMDC risk score (P = .818).

The DCR was 58% in the pembrolizumab/axitinib group vs 43% in the nivolumab/ipilimumab group (P = .440).

Notably, LIPI score was significantly associated with OS (poor LIPI: HR, 8.18; P = .004) and PFS (intermediate LIPI: HR, 2.4; P =.048; poor LIPI: HR, 8.59; P <.001). Moreover, LIPI predicted for response in patients who received nivolumab/ipilimumab (P = .024).

“LIPI score was significantly associated with OS and PFS and was predictive of ORR in the nivolumab/ipilimumab group,” the study authors concluded. “Prospective studies are needed to confirm these results.”

Reference

Carril-Ajuria L, Colomba E, Romero-Ferreiro C, et al. Efficacy of first-line combination therapy in metastatic renal cell carcinoma (mRCC) patients (pts) with poor performance status (PS). J Clin Oncol. 2022;40(suppl 6):320. doi:10.1200/JCO.2022.40.6_suppl.320

Related Videos
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
There is no absolute age cutoff where CAR T cells are contraindicated for those with large B-cell lymphoma, says David L. Porter, MD.
David L. Porter, MD, emphasizes referring patients with large B-cell lymphoma early for CAR T-cell therapy consultation.
Related Content